Impedance cardiography helps identify patients at risk of heart failure

2 October 2005

San Diego, Calif., USA. A study conducted by the San Diego Veterans Administration Healthcare System and University of California found that impedance cardiography (ICG) and BNP testing can help predict heart failure-related.

The results were annouced by CardioDynamics, developer of impedance cardiography technology, at the Ninth Annual Heart Failure Society of America (HFSA) Scientific Meeting held in September in Florida.

Researchers from the San Diego Veterans Administration Healthcare System and University of California, San Diego School of Medicine studied 331 patients undergoing routine outpatient echocardiography to determine whether the combination of ICG and BNP (b-type natriuretic peptide) testing provided a useful strategy to identify high-risk patients likely to develop heart failure-related events.

The patients were followed up to one year for clinical events (emergency room visits, hospital admissions and cardiac-related deaths). Patients with left ventricular dysfunction are at a high risk for morbidity and mortality, and it remains difficult to predict which patients are most likely to have clinical events.

Echocardiography is considered the gold standard for diagnosis of left ventricular dysfunction, but its cost, physician office reimbursement restrictions, and dependency on trained technicians limits availability and prevents its frequent use.

The study concluded that ICG and BNP testing significantly add to the ability to risk stratify and predict future heart failure-related events.

The study is important because it demonstrates the additive ability of ICG when paired with BNP, a common blood test used in heart failure, to identify patients with a higher likelihood of future heart failure events.

The Company also announced that renowned heart failure specialist, Milton Packer, M.D., Director, Center for Biostatistics and Clinical Science at the University of Texas Southwestern Medical Center at Dallas, and researchers from over 20 multi-national centers met at the HFSA meeting to finalize the protocol for the Company's next multi-center heart failure study, PREVENT-HF. PREVENT-HF is a randomized, controlled trial and is the follow-on study to the previously reported PREDICT study. The purpose of PREVENT-HF is to demonstrate whether use of ICG will allow physicians to intervene earlier and more aggressively in high-risk patients, thereby reducing heart failure events and cost as compared to standard care.

To top

To top